ArticleJournal of thoracic disease2026
Nontuberculous mycobacterial pulmonary disease and lung cancer: a retrospective case series.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of nontuberculous mycobacterial pulmonary disease (NTM-PD) has increased worldwide. However, the clinical characteristics and optimal management of patients with concomitant lung cancer and NTM-PD remain poorly understood. This retrospective case series aimed to investigate the clinical characteristics, microbiological findings, treatment strategies, and clinical outcomes of patients with lung cancer complicated by NTM-PD. Methods: We retrospectively reviewed the clinical data of 13 patients with concomitant lung cancer and NTM-PD at our institution between January 2020 and January 2025. Demographic characteristics, clinical manifestations, microbiological findings, tumor stage, histological subtype, driver gene alterations, treatment strategies, and clinical outcomes were collected and analyzed. NTM species were identified by metagenomic next-generation sequencing (mNGS). Results: A total of 13 patients (8 men and 5 women) were included, with a median age of 64 years (interquartile range, 59.5-71.0 years). Adenocarcinoma was the most common histological subtype (n=7). The predominant NTM species were Conclusions: Among patients with lung cancer complicated by NTM infection, the predominant species were MAC and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.